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Abstract
Background: Alternative splicing provides a major mechanism to generate protein diversity. Increasing evidence
suggests a link of dysregulation of splicing associated with cancer. While previous genomic-based studies
demonstrated the expression of a handful of tumor-specific isoforms, genome-wide alterations in the balance
between isoforms and cancer subtypes is understudied.
Result: We systematically analyzed the isoform-level expression patterns and isoform switching events of 819 breast
tumor and normal samples assayed by mRNA-seq from TCGA project. On average, 2.2 isoforms per gene were
detected and 67.5 % of detected genes (i.e. expressed) showed 1–2 isoforms only. While the majority of isoforms
for a given gene were positively correlated with each other and the overall gene level, 470 pairs of isoforms displayed
an inverse correlation suggesting a switching event. Most of the isoform switching events were associated with
molecular subtypes, including a Basal-like-associated switching in CTNND1. 88 genes showed switching independent
of subtypes, among which the isoform pattern of PRICKLE1 was associated with a large genomic signature of
biological significance.
Conclusion: Our results reveal that the majority of genes do not undergo complex mRNA splicing within breast
cancers, and that there is a general concordance in isoform and gene expression levels in breast tumors. We identified
hundreds of isoform switching events across breast tumors, most of which were associated with differences in tumor
subtypes. As exemplified by the detailed analysis of CTNND1 and PRICKLE1, these isoform switching events potentially
provide new insights into the post-transcriptional regulatory mechanisms of tumor subtypes and cancer biology.
Background
Gene expression patterns have been extensively studied
due to the widespread use of DNA microarrays. Now
with the advent of RNA-sequencing (RNA-seq), alter-
native splicing of genes can also be studied on a
genome-wide level. Alternative splicing provides an
additional layer for gene regulation and is a major
mechanism to drive proteome diversity. Recent esti-
mates indicate that the overwhelming majority of
protein-coding genes in humans contain multiple
exons, and more than 90 % of them produce multiple
transcripts [1]. In normal tissues, alternative splicing is
regulated according to the cell type, developmental
stage, external stimulating signal, etc., and is coupled
with nonsense-mediated mRNA decay pathway to regu-
late gene expression [2]. However, in several diseases
including cancer, dysregulated alternative splicing can
result in translation of aberrant proteins that can con-
tribute to tumorigenesis. Although the definitive role of
many mRNA isoforms is not clear, increasing evidence
has suggested a link between alternative splicing and
cancer causation [3, 4]. Investigations of alternative
splicing patterns and their contribution to cancer will
deepen our understanding of the oncogenic process,
and potentially provide novel biomarkers [5].
A few cancer-related alternative splicing events have
been extensively investigated. For instance, BCL-X gives
rise to two functionally antagonistic isoforms: an anti-
apoptotic isoform BCL-Xl and a short pro-apoptotic
isoform BCL-Xs. The up-regulation of BCL-Xl and/or
down-regulation of BCL-Xs has been observed in several
cancer types [6–8]. Another well-characterized gene,
MDM2, expresses a remarkably complex splicing
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pattern. Isoforms that lack part of the p53-binding do-
main are unable to form p53-MDM2 interactions to
regulate its degradation [9], leading to p53-dependent ef-
fects of gene expression in tumors [10–13].
In breast cancer, microarray and qRT-PCR-based stud-
ies have identified genes that express multiple splice var-
iants including CD44, ESR1, ESR2, TP53, SYK, BRCA1
[14–16], and some of these are associated with specific
breast cancer subtypes [16]. RNA-seq technology offers
an accurate and unbiased approach to explore the het-
erogeneity of mRNA splicing on the global scale. Recent
RNA-seq-based studies provided catalogues of alterna-
tive splice variants that are specific to tumor types, cell
lines, or a subpopulation of primary tumors [17, 18], but
most of the discovery was based on small cohorts. Cur-
rently, the increasing accumulation of RNA-seq data
published by large consortiums, coupled with advanced
statistical and computational tools, enables the extensive
exploration of the diversity of alternative splicing with
higher confidence. Here, we performed genome-wide
analysis on a set of 819 breast tumors and normal
tissues from the Cancer Genome Atlas (TCGA) [19].
We found that thousands of genes show alternative
splicing, but that most isoforms of a gene are highly cor-
related in their overall gene expression patterns. Inter-
estingly, only a small set of genes displayed dramatic
isoform switching events.
Results
General isoform expression characteristics across 819
breast samples
In order to begin to study the complexity of mRNA iso-
form diversity, we used the isoform level expression data
from 728 breast tumors and 91 normal breast tissues
from TCGA breast data set (TCGA BRCA) [19, 20]. The
summary of patient characteristics for this sample set is
presented in Additional file 1: Table S1. Transcript abun-
dance was estimated by RSEM [21], based on the UCSC
known genes annotation (GAF2.1), which consists of
20,531 genes and 73,599 previously determined tran-
script definitions. In this paper, we used these known
isoform definitions and did not perform any de novo
isoform discovery or derive any new isoform definitions.
In addition, we used RSEM to assign expression values
to individual isoforms, which is a method where the
common exon reads are proportionally assigned based
upon the ratio of reads mapping to isoform unique
regions.
Across the 819 samples, an average of 40.5 % of the
73,599 transcripts had less than one normalized read
count and 25.5 % isoforms were detected in less than
10 % samples (Fig. 1a and b); these were not used for
any subsequent analyses. 25.4 % of transcripts had more
than 100 reads and approximately 35.1 % of transcripts
were expressed in more than 90 % patients. To restrict
the degree of sparsity while including the majority of the
detected transcripts, analyses in this study were per-
formed on the set of transcripts with at least 3 normal-
ized read counts (i.e. detected) in more than 60 %
patients, which included 37,267 isoforms from 16,765
genes (see Methods).
Complexity and consistency of isoform expression
Of the 16,765 genes detected, 7258 expressed only 1 iso-
form, 4062 expressed 2 isoforms, and 5445 expressed 3 or
more isoforms (Fig. 1c). According to this analysis, the
majority of genes (67.5 %) showed simple isoform patterns
of only one or two isoforms. In contrast, 43 genes were
associated with more than 10 detected isoforms, which
suggests that alternative splicing is potentially crucial in
regulating the function of these genes (Additional file 2:
Table S2). Functional analysis of these 43 genes using DA-
VID Tools [22] indicates a moderate enrichment of GO
terms of cell cycle process, chromatin modification, apop-
tosis and DNA repair (Additional file 3: Table S3).
Despite the expression of isoforms for thousands of
genes, the vast majority of alternatively spliced tran-
scripts were correlated with the other transcripts of the
same gene. The median Pearson correlation score of the
42,356 alternatively spliced isoform pairs was 0.28, with
only 14.2 % pairs of isoforms negatively correlated
(Fig. 1d). In fact, there were ~14,000 isoform pairs where
the correlation was >0.4. There was not a significant
association between the correlation of isoform pairs
and the isoform expression level, or the isoform lengths
(data not shown), although we do note that it is more
likely to detect multiple isoforms in genes that show
moderate to high expression levels.
On a global scale, the isoform expression patterns
recapitulate the genomic profiles taken from the gene
level data, which is not surprising given the overall high
correlation in expression observed between isoforms of
the same gene. To examine isoform level expression pat-
terns, we performed unsupervised hierarchical clustering
of the top 6000 most variably expressed transcripts
(Fig. 2a). The intrinsic breast cancer subtypes, and their
defining gene sets, could be clearly identified including
basal-like, luminal and HER2-Enriched expression signa-
tures (Fig. 2b-d); however, now these gene clusters were
often populated with multiple isoforms from the same
gene that were typically co-clustered together, such as
multiple isoforms of ESR1 and SCUBE2 in the luminal
cluster (Fig. 2c), and multiple isoforms of HER2/ERBB2
in the HER2 amplicon cluster (Fig. 2d). Overall, no new
gene clusters/signatures were identified when using iso-
form level data, but instead, greater detail was included
in all previously identified gene clusters.
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Identification of isoform switching pairs
The majority of alternatively spliced isoforms from the
same gene showed correlated expression, therefore, we
purposely searched for those genes that showed “isoform
switching” or alternative usage of isoforms; we define
“switching” as isoform pairs that were negatively corre-
lated. Given the sparsity of much of the isoform data, we
focused on a specific type of isoform switching, namely
the switching of the predominant isoform to an alterna-
tive isoform(s), where the predominant isoform was
identified as the transcript with the greatest upper quar-
tile abundance for each gene. 2,110 pairs of predomin-
ant/alternative isoforms showed significant negative
correlation based on a linear regression model.
We noted, however, that there was at least one tech-
nical effect that was dramatically affecting this apparent
“switching” result. A difference in RNA integrity (i.e.
RIN score) contributed to a large proportion of the
2,110 predominant/alternative switching events. Hier-
archical clustering of the expression data using the
2,110 pairs of isoforms separated the samples into two
clusters that were significantly associated with RIN
even in this set of TCGA samples where all but two
normal samples had RINs >7 (Additional file 1: Table
S1, Additional file 4: Figure S1A and B). Two groups of
isoforms showed significantly high and low expression
in the cluster of samples with low RINs (aka, sample
Cluster 1) respectively, which represent 917 pairs of
isoform switching (Additional file 5: Table S4). Among
them, 893 highly expressed isoforms were the shorter
isoforms of the pairs. Therefore, it suggests that the ob-
served relatively higher level of short isoforms is poten-
tially caused by loss of RNA integrity. After adjusting
for the RIN bias, a modified linear regression model
identified 470 pairs of isoform switching candidates from
452 genes (Additional file 4: Figure S1C, Additional file 6:
Table S5). Functional ontology analysis of these genes
suggests the involvement of a multitude of biological
pathways including RNA processing (i.e. splicing), protein
localization, cell cycle, methylation and chromatin
A B
C D
Fig. 1 General isoform expression characteristics across 819 breast samples. a Proportion of detected isoforms using distinct cutoff to call isoform
detection in 819 breast samples (blue lines) and on average (red line). b Distribution of isoforms expression across samples using different cutoff
for isoform detection. c Distribution of the number of detected isoforms for each gene. d Pearson correlation of the abundance of detected
isoform pairs of the same gene
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modification (Additional file 7: Table S6); thus as would be
expected, our analysis identified many genes previously
known to undergo RNA processing/splicing.
Investigation of isoform switching: subtype specific
events
Previous efforts to catalog alternative splicing events
by comprehensive microarray-based screening have
revealed that many such events are specific to tumor
subtypes [23]. Therefore, we sought to determine
whether the 470 switching candidates were ubiquitous
in all breast samples or were unique to certain sub-
types. Every molecular breast cancer intrinsic subtype
[24] was correlated with a number of switching
events, with the basal-like subtype exhibiting the most
compared to the others (Table 1, Additional file 6:
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Fig. 2 Hierarchical clustering analysis of the top 6000 most variably expressed transcripts. a Overview of the clustering diagram of 728 breast
tumors and 91 normal samples. Gene signatures of (b) basal, (c) luminal and (d) Her2 subtype were identified, with multiple isoforms from the
same biomarker genes co-clustered
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Table S5). 229 pairs of isoforms from 224 genes dis-
played isoform switching in basal-like samples as
compared to luminal (Additional file 8: Table S7). Intri-
guingly, among them, 49 pairs did not show a differ-
ence at the gene expression level (Additional file 8:
Table S7), which highlights that for a small number of
genes, alternative splicing provides additional genetic
complexity that is not reflected by total gene expression
levels.
Recently Hoadley et al. [25] demonstrated that the
breast basal-like subtype showed striking similarity with
squamous cancers on many genomic levels including
gene expression patterns, somatic mutations and DNA
copy number alterations. This commonality even ap-
plied to some alternatively spliced genes/transcripts in-
cluding the well-known ΔNp63. The TCGA PanCan12
Squamous Genomic Group contained Head and Neck
Squamous (HNSC), Lung Squamous (LUSC), and a few
Bladder cancers with squamous features (BLCA). We
therefore sought to examine whether these breast
basal-like tumor associated isoform switching events
were similarly observed in the TCGA Squamous Gen-
omic Group tumors. We analyzed all 3308 tumor sam-
ples of the TCGA PanCancer12 study [25] for these
basal-like isoform patterns. 40/229 basal-like associated
isoform pairs showed consistent switching patterns be-
tween Squamous Genomic Group and PanCan Lung
adenocarcinoma (LUAD)-enriched Group, and between
PanCan Luminal Breast versus Basal-like Breast
Groups, similar to what was observed here when
comparing the basal-like and luminal breast subtypes
(Additional file 8: Table S7). For example, CTNND1
had significant differences in comparing the expression
pattern of a pair of isoforms, both with high detection
rate, in luminal and basal-like samples, even though no
statistical difference was seen in the total gene expres-
sion level comparison (Fig. 3a); this same switching pat-
tern was also seen in the PanCan12 3308 tumor data
set when we focused on the Squamous Genomic Group
versus LUAD-enriched Group (Fig. 3b), thus suggesting
that this pattern is conserved across related cell and/or
tumor subtypes. CTNND1 may generate up to 30
isoforms by alternative inclusion/exclusion of 21 exons.
Among them, 14 isoforms were detected in breast
tumors for this study. Despite this complex splicing
pattern, only the isoform pair of uc001nlo.3 and
uc001nlt.3 was identified to have the switching event.
These two transcripts both use the same ATG start site,
but differ in the alternative inclusion of exon 20 of the
gene, where a nuclear export sequence (NES) is located
(Fig. 3c).
To exclude the possibility that the observation was
caused by ambiguous read alignment, we validated the
splicing pattern by de novo assembly (Additional file 9:
Figure S2A). 10 samples that provided the highest rela-
tive expression level of either isoform respectively were
pooled and de novo assembled to dissect the gene struc-
ture. In both subsets, only contigs consistent with the
‘sample-specific predominant isoform’ (i.e. the isoform
with relatively high expression level in the 10 tumor
samples being tested) were identified. This result offers
additional evidence for the existence of two subsets of
samples that show opposite trend in the usage of exon
20 of CTNND1.
Investigation of isoform switching: Non-subtype
associated events
We identified 88 pairs of isoforms with a switching pat-
tern that were not associated with intrinsic molecular
subtype, however, we noted a biological feature that con-
founded this analysis. Namely for many of these appar-
ent switching events, one of the isoforms was a very rare
event that only happened in a few samples. To address
this feature objectively, the splicing patterns of these 88
genes were interrogated by unsupervised k-means clus-
tering, and only the expression of 16 isoform pairs strati-
fied samples into two clusters in which both isoforms
were detected and were inversely correlated, and where
the size for both clusters was greater than 50 samples
per cluster/group (Additional file 6: Table S5).
As an example, we further investigated the isoform
pair uc010skw.1/uc001rnl.2 of PRICKLE1. While the
gene expression level of PRICKLE1 was not significantly
different between tumor and normal samples, two sub-
populations were identified based on the isoform pattern
(Fig. 4a). The two clusters have comparable RIN scores,
excluding the possibility that the differential expression
of transcripts was confounded by partial degradation.
The alignment of the two transcripts was validated by de
novo assembly of the samples with significant differential
expression of PRICKLE1 isoform pair (Additional file 9:
Figure S2B).
PRICKLE1 has an alternative 3’ splice site with isoform
uc001skw.1 containing three additional nucleotides in
exon 7 compared to isoform uc001rnl.2 (Fig. 4b). Exon 8
and part of exon 7, including the alternative splice site,
Table 1 Subtype specificity of isoform switching pairs
subtype-
associated
isoform pairs
subtype-
associated
genes
subtype-associated isoform
pairs, no difference in gene
abundance
Basal 246 363 55
Her2 105 235 51
LumA 196 308 56
LumB 127 263 49
Normal 239 390 36
Luminal vs. Basal 229 361 49
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Fig. 3 Isoform expression and gene structure of CTNND1. a Gene and isoform expression of CTNND1 in the TCGA BRCA dataset. The total gene
expression of CTNND1 provides comparable level in luminal and basal tumors, whereas the abundance of two CTNND1 isoforms, uc001nlo.3 and
uc001nlt.3, exhibit inversely correlated differential expression in luminal and basal tumors. b Isoform expression of CTNND1 in the TCGA PanCan12
data set. The expression pattern of uc001nlo.3 and uc001nlt.3 pairs is similarly observed in the PanCan12 Luminal BRCA and Basal BRCA tumors, as well
LUAD and Squamous clusters. c CTNND1 gene structure. The two isoforms are transcribed from the same transcription start site and provide
alternative splicing in exon 20 (red arrow)
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Fig. 4 Isoform expression and gene structure of PRICKLE1. a Expression pattern of PRICKLE1 isoforms uc010skw.1 and uc001rnl.2. Two expression
patterns (red and black) were identified by K-means clustering in subsets of breast samples. b PRICKLE1 gene structure.uc001skw.1 and uc001rnl.2
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constitute the 5’ UTR sequence of PRICKLE1. While
both splice sites were validated by contigs from de novo
assembly, the smaller exon 7 was only assembled in the
subset of samples that are enriched with uc001rnl.2.
These two transcripts have no difference in the coding
regions, however, a closer scrutiny of the PRICKLE1 se-
quence reveals that the alternative usage of this splice
site affects the structure of 5’ UTR. An internal loop is
predicted to be introduced in the hairpin structure of
uc001skw.1 (Fig. 4c). Moreover, several binding motifs of
RNA-Binding Proteins (RBP) were identified in the
alternative 3’ splice site and the loop region (Fig. 3c).
One of the RBP potentially being affected is SRSF2,
which regulates splicing switches between pro- and anti-
apoptotic isoforms of at least four genes: c-flip, caspase
8, caspase-9 and BCL-X [3, 8]. Of them, the abundance
of CASP8 isoform uc010ftc.1 was associated with this
PRICKLE1 isoform pattern (data not shown). These re-
sults suggest that the RBP binding in the 5’ UTR region
potentially contributes to the regulation of PRICKLE1
function or alters it’s interaction with other genes.
We next assessed the potential effect of this PRIKLE1
alternative splicing event on global expression patterns
via supervised gene expression analysis using Signifi-
cance Analysis of Microarrays/SAM [26]. The expression
ratio of uc001skw.1 versus uc001rnl.2 was used as the
supervising parameter and was significantly correlated
with 1059 genes (FDR = 0; termed PRICKLE1-alt genes)
(Additional file 10: Table S8). We then used these 1059
genes in a hierarchical clustering analysis across the 819
samples and identified 4 distinct gene expression signa-
tures (Fig. 5).
Gene cluster A, which was more highly expressed in
tumors with the PRICKLE1 uc010skw.1 isoform, was
prickle1 cluster
RIN group
PAM50
 D
 -2.00
 -1.33 
 -0.67 
 0.00 
 0.67 
 1.33 
 2.00 
Basal
Her2
LumA
LumB
Normal
low
high
RIN group
PRICKLE1
isoform cluster
cluster 1
cluster 2
PAM50 subtype
 A
 B
 C
Fig. 5 Hierarchical clustering analysis of the gene signatures associated with the isoform expression pattern of PRICKLE1. 1059 genes are
significantly correlated with the ratio of uc010skw.1 and uc001rnl.2, and are not associated with PAM50 subtype or RIN score. PRICKLE1-based
clusters identified by K-means clustering were color coded consistent with Fig. 3a. RIN group displays samples with high (>8.7, median RIN) and
low RIN score (≤8.7). Four gene expression signatures (a-d, shown by side color bars) are identified to be involved in cancer hallmarks
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enriched with genes involved in inflammatory response
and activation of immune response (Fig. 5). A potential
tumor suppressor gene SYK is in this cluster; SYK has
been identified as a regulator of epithelial cell growth
and its splicing pattern alters cell survival in breast and
ovarian cancer [27]. Gene cluster B was highly enriched
with genes of extracellular matrix and/or genes that
regulate signal transduction pathways for Epithelial-to-
Mesenchymal transition (EMT), including RBFOX2
(RBM9), which has been demonstrated to regulate the
EMT splicing in a panel of breast cancer cell lines and
primary tumors [28, 29]. Other intriguing genes included
JAK1 that encodes a protein tyrosine kinase that medi-
ates the cytokine receptor signaling via activation of
STAT transcription factor. Interestingly, JAK2 was also
selected in the PRICKLE1-alt signature, which regulates
STAT-independent oncogenic pathway in addition to the
JAK/STAT pathway [30]. Other cancer-associated genes
in Cluster B include ZEB2, NOTCH1, and FAT1.
Gene cluster C was enriched with genes that regulate
phosphorylation and transcription. Two serine/threonine
protein kinases, ATM and MAP3K2, were identified,
suggesting its involvement in DNA repair and apoptosis
pathways. Cluster D contained genes with function in
oxidative phosphorylation and ATP synthesis coupled
electron transport. Prior studies have revealed that
deregulated energy metabolism, such as glycolytic switch,
is an emerging hallmark of cancer [31]. Therefore,
genes of cluster D are potentially involved in repro-
graming of energy metabolism in cancer cells to sup-
port cell growth and division. None of these gene
signatures, nor the expression of PRIKLE1 itself, were
prognostic.
Discussion
Changes in alternative splicing could lead to, or contrib-
ute to, tumor formation. Genomic studies have revealed
that more than 15,000 isoforms are associated with sev-
eral cancer types [18, 29]. In this study, we systematically
analyzed all the annotated transcripts/isoforms in UCSC
database in 819 TCGA breast tumor and normal sam-
ples assayed by RNA-seq. Despite the increased com-
plexity of transcripts compared to genes, on average
only 2.2 isoforms per gene were detected. However, a
few genes produced highly complex splicing patterns,
indicating their potential regulation on the splicing
level. Past work has established links with cancer for
some of these genes; for example, NCOR1, a nuclear
co-repressor with 14 isoforms detected, has been pos-
tulated to regulate retinoic acid and thyroid hormone
receptor protein levels and to disrupt PPARα/γ signal-
ing in prostate cancer [32].
For most genes, including those with complex splicing
patterns, the expression levels of genes and isoforms
from the same gene were positively correlated across
these samples, even in genes with low levels of expres-
sion. On a first pass analysis to identify genes showing
isoform switching (i.e. negatively correlated isoforms),
78 % of inversely correlated isoforms showed significant
difference in RNA integrity (i.e. RIN scores), although
no association was observed between the isoform correl-
ation and isoform lengths. Of note, 636/819 samples had
a RIN score of at least 8, which suggests that even for
high-quality samples, investigation of relative expression
of transcripts must still account for RNA integrity. In
our study, we adopted a computational strategy to
minimize the effect of RIN. An alternative approach may
be to use RNA-seq library preparation protocols that
don’t rely on polyA enrichment, such as Ribo-Zero with
random priming. We observed in our previous studies
that Ribo-Zero provided less biased 5’-to-3’ coverage,
even in FFPE samples [33].
Based on the global expression profile and after ac-
counting for RIN, we identified 470 pairs of predomin-
ant and alternative isoforms that showed “switching”
events; most of them were associated with intrinsic mo-
lecular subtypes. As exemplified by CTNND1, the
switching pattern between basal-like and luminal breast
tumors was similarly observed in the PanCan12 Squa-
mous Genomic Group versus PanCan12 Lung
Adenocarcinoma-enriched Group, which is indicative of
another common characteristic of breast basal-like and
squamous tumor subtypes [25]. CTNND1, also known
as p120, has been identified to provide both oncogenic
and tumor suppressor functions. p120 regulates the
turnover of cadherin and maintains the stability of
adherins junctions at the plasma membrane [34]. In
addition, it also modulates Rho GTPase activity as an in-
hibitor or activator depending on the cellular context
[35, 36]. p120 can also translocate to the nucleus and
interacts with the transcriptional repressor Kaiso [37],
relieves the repression of its target genes such as
WNT11 and CyclinD1 [38, 39], and indirectly modulates
the Kaiso-dependent sequestering of β-catenin and TCF/
LEF transcription factor. Therefore, the localization of
p120 in specific cellular compartments is likely to be
functionally relevant. Four ATG start sites located at
amino acids 1, 55, 102, 324 initiate the expression of iso-
forms 1–4 in CTNND1. Three other exons (exon 18(A),
exon 20(B) and exon 11(C)) are also alternatively in-
cluded in the transcripts [40]. A nuclear export sequence
(NES) is located at exon 20(B). While emerging interest
has been focused on the alternative N-terminal and the
regulatory phosphorylation domain, the function of
nuclear localization sequences (NLS) and NES in p120 is
still unclear.
Here we identified a subtype-associated switching
event of CTNND1 isoform 3A(uc001nlt.3) and isoform
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3AB(uc001nlo.3), in which isoform 3A(uc001nlt.3) is
predominantly expressed in the breast basal-like subtype
and the PanCan12 Squamous group. We hypothesize
that it potentially suggests the involvement of exon B/
NES sequence in regulating nucleo-cytoplasmic shuttling
activity. Past work has demonstrated that nuclear Kaiso
expression is enriched in basal-like/triple-negative breast
cancers and in BRCA1 associated invasive breast cancer,
and is inversely correlated with cytosolic p120 [41].
Here, we showed that isoform 3A, which lacks the exon
B/NES domain, is enriched in the basal-like subtype.
Collectively, it suggests the link between the missing of
exon B and the low cytosolic p120 level. Of course, add-
itional experiments are required to validate the role of
NES, but our study here reveals that, in addition to the
balance of isoform 1 and 3 that is known to be critical
for cell motility, the ratio of an isoform with or without
NES might also affects the localization and consequently
the function of p120.
In contrast to switching events correlating with sub-
type, many fewer were seen that were independent of
subtype (i.e. 88 pairs). The switching of PRICKLE1
uc010skw.1 and uc001rnl.2 was one such event. Interest-
ingly, PRICKLE1 isoform supervised gene expression
analysis revealed its correlation with >1000 genes (Fig. 5)
including tumor suppressors, transcription regulators,
and genes that are crucial for EMT and energy metabol-
ism. Previous studies demonstrated that PRICKLE1 reg-
ulates two pathways in cancer. In hepatocellular
carcinoma (HCC), PRICKLE1 negatively regulates Wnt/
β-Catenin pathway by binding to DVL3 and facilitating
its ubiquitination/degradation [42]. Alternatively, in
chronic lymphocytic leukemia (CLL), PRICKLE1 medi-
ates migration and transendothelial invasion of CLL cells
via DVL3-independent Wnt/planar cell polarity (PCP)
signaling pathway [43]. None of the PRICKLE1-alt gene
clusters we identified showed an enrichment of genes of
the Wnt/β-Catenin or Wnt/PCP pathway. Moreover, the
alternative splice site involved in the switching does not
disrupt the protein coding sequences. Computational
analysis of the transcript sequences provided a lead for
its post-transcriptional regulation; namely the alternative
splice site at the 5' UTR region, and the hairpin struc-
ture of the flanking region, are enriched with putative
RBP binding domains, and thus in breast cancer
PRICKLE1 function may be regulated by alternative RBP
binding abilities due to alternative stem-loop structures
in the 5’ UTR.
Conclusions
In summary, we provide a global profile of annotated
transcripts in breast tumors and normal samples, and
our data demonstrate the general agreement in isoform
and gene level expression. Isoform switching events were
identified, but most correlated with subtype, and only a
minority were subtype-independent. These results iden-
tify many novel genomic events that are involved in
breast tumor biology and detail for the first time, the
precise alternative splicing events that occur in breast
cancer and that eluded the field before the advent of
RNA-sequencing.
Methods
Read processing and alignment
RNA-sequencing data for all TCGA BRCA and TCGA
PanCan samples were obtained from https://tcga-data.n-
ci.nih.gov/tcga/. All samples were sequenced using pre-
viously published methods [25]. The alignment and
quantification was performed by MapSplice [44] v12_07
and RSEM [21] v1.1.13 respectively, using the reference
transcriptome of UCSC hg19 GAF2.1 [45] for known
genes, as described in [33]. Data was normalized to a
fixed upper quartile within each sample.
Quantification of isoform abundance
The transcript/isoform abundance was filtered by requir-
ing the RSEM normalized count to be ≥3 for each tran-
script. The detected transcript sets were defined as
transcripts that were reported present in >60 % samples
and with 3 or more normalized reads. The log2 trans-
formed transcript abundance was reported. For each
gene, the predominant isoform was determined as the
transcript that provided the greatest upper quartile value
across all samples.
Identification of isoform switching events
The isoform switching events in all samples (both tumor
and normals) were identified using a linear regression
model: ygi ~ β1*xb + β2*xgi, where ygi is the alternative
isoform, xgi is the predominant isoform, xb is RIN score.
The events were defined as isoform pairs with (i) β2 < 0;
(ii) p-value for xb > 0.2 and (iii) p-value for xgi < 0.05.
Isoform switching events associated with subtype
The expression pattern of isoform pairs was character-
ized by the ratio of alternative isoform to predominant
isoform. The Student’s t-test was used to estimate the
correlation of the isoform pairs and tumor subtype as
previously determined by the PAM50 algorithm [24, 25],
with the significance determined at p-value < 0.05.
Validation and analysis of the sequence of isoform
switching pairs
For each isoform of the switching pairs of CTNND1 and
PRICKLE1, 10 samples with the greatest relative abun-
dance were selected. Reads mapped to the gene of inter-
est were pooled and de novo assembled using Trinity
[46]. Assembled contigs were then mapped to the
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genome by BLAT [47] and visualized by IGV [48]. The
annotation of transcript sequence and the structure of 5’
UTR sequence of PRICKLE1 were retrieved from UCSC
genome browser [45]. RBPmap [49] was then used to
predict the RBP binding sites in the PRICKLE1 5’ UTR
region.
Differential gene expression associated with isoform
switching pairs
The expression pattern of PRICKLE1 transcript of
uc001rnl.2 and uc010skw.1 was profiled, and two
subpopulations of samples with differential usage of
PRICKLE1 isoforms were identified by K-means cluster-
ing (Fig. 4a). Quantitative SAM analysis was performed
to identify genes that showed differential expression
associated with the ratio of PRICKLE1 transcript of
uc001rnl.2 to uc010skw.1. The gene list was obtained
with a FDR of 0 (Additional file 10: Table S8). Four gene
signatures were identified by the hierarchical clustering
analysis and its functional annotation was performed by
DAVID Tools [22].
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